The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial examined whether patients treated with anti-IL1β (Canakinumab) for atherosclerosis had decreased incidence of cancer. This evidence concerns the gene IL1B and cancer.